{"address1": "32 Wiggins Avenue", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 457 9000", "fax": "781 305 9720", "website": "https://www.anikatherapeutics.com", "industry": "Medical Devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 345, "companyOfficers": [{"maxAge": 1, "name": "Dr. Cheryl Renee Blanchard Ph.D.", "age": 58, "title": "Pres, CEO & Director", "yearBorn": 1964, "fiscalYear": 2021, "totalPay": 1259971, "exercisedValue": 27964, "unexercisedValue": 77481}, {"maxAge": 1, "name": "Mr. Michael L. Levitz", "age": 48, "title": "Exec. VP, CFO & Treasurer", "yearBorn": 1974, "fiscalYear": 2021, "totalPay": 683142, "exercisedValue": 0, "unexercisedValue": 24381}, {"maxAge": 1, "name": "Mr. David  Colleran J.D.", "age": 50, "title": "Exec. VP, Gen. Counsel & Corp. Sec.", "yearBorn": 1972, "fiscalYear": 2021, "totalPay": 649061, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Nunes", "title": "VP of Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ian W. McLeod", "title": "VP & Chief Accounting Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Namaroff", "age": 59, "title": "Exec. Director of Investor Relations & Corp. Communications", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Chase", "title": "Sr. VP of International Sales & Marketing", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben  Joseph", "title": "VP of Commercial & Corp. Devel.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Funiciello", "title": "VP of HR", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 3, "compensationRisk": 5, "shareHolderRightsRisk": 5, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400, "priceHint": 2, "previousClose": 25.29, "open": 26.25, "dayLow": 24.485, "dayHigh": 26.25, "regularMarketPreviousClose": 25.29, "regularMarketOpen": 26.25, "regularMarketDayLow": 24.485, "regularMarketDayHigh": 26.25, "payoutRatio": 0.0, "forwardPE": 842.0, "volume": 105904, "regularMarketVolume": 105904, "averageVolume": 83536, "averageVolume10days": 69920, "averageDailyVolume10Day": 69920, "bid": 0.0, "ask": 0.0, "bidSize": 800, "askSize": 900, "marketCap": 369627072, "fiftyTwoWeekLow": 20.12, "fiftyTwoWeekHigh": 32.51, "fiftyDayAverage": 27.536, "twoHundredDayAverage": 27.36535, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 370066304, "profitMargins": 0.0, "sharesOutstanding": 14609700, "sharesShort": 432469, "sharesShortPriorMonth": 463014, "sharesShortPreviousMonthDate": 1680220800, "dateShortInterest": 1682640000, "sharesPercentSharesOut": 0.0296, "heldPercentInsiders": 0.023610001, "heldPercentInstitutions": 0.91041, "shortRatio": 6.42, "shortPercentOfFloat": 0.040599998, "impliedSharesOutstanding": 0, "bookValue": 19.526, "priceToBook": 1.2936598, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1680220800, "trailingEps": -0.99, "forwardEps": 0.03, "pegRatio": -2.16, "52WeekChange": 0.1929245, "SandP52WeekChange": 0.046755195, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ANIK", "underlyingSymbol": "ANIK", "shortName": "Anika Therapeutics Inc.", "longName": "Anika Therapeutics, Inc.", "firstTradeDateEpochUtc": 736435800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef258dda-d89e-3407-b824-c5d0079911f4", "messageBoardId": "finmb_328641", "gmtOffSetMilliseconds": -14400000, "currentPrice": 25.26, "targetHighPrice": 38.0, "targetLowPrice": 28.0, "targetMeanPrice": 33.0, "targetMedianPrice": 33.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "revenuePerShare": 10.73, "grossProfits": 96775000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "trailingPegRatio": null}